Learn how Signant Health helped one sponsor complete a mid-study switch to a direct-to-patient clinical supply model. Date Published: Oct 07, 2020 Whitepaper Clinical randomization and trial supplies systems have traditionally focused on managing supplies for sites. The increase in decentralized trials, expedited by the COVID-19 pandemic, has prompted a rapid shift towards more flexible, direct-to-patient models of study supply management and a new emphasis on patient experience. This paper explains how a real-world case study in which Signant helped a sponsor change to a direct-to-patient model mid-study has proven the validity of the model, and it outlines recommendations and best practices when employing a direct-to-patient model of trial supply management. Share: LinkedInTweet Recommended Resources 3 Themes and Takeaways From FDA’s Draft Guidance on DCTs Download Now Whitepaper Computerized Adaptive Tests Using PROMIS CAT Download Now Whitepaper The EMA Recommendation Paper on Decentralized Elements in Clinical Trials: An Overview Read Our White Paper Whitepaper